| Objective:This article explores the relationship between Her-2 expression and clinicopathological features in patients with gastric cancer.The effect of Her-2 on the survival of patients was retrospectively analyzed.Further analysis of whether Her-2 may be an independent factor in the prognosis of gastric cancer.Provides basis for individualized treatment and prognosis of gastric cancer in clinical work.Methods:A total of 192 patients who were diagnosed and treated with pathologically proven gastric cancer at the First Affiliated Hospital of University of South China from 2009.01 to 2013.09 were collected as research subjects.The Her-2 protein in gastric cancer tissues was detected by conventional immunohistochemistry(IHC).Analysis of Her-2 protein expression and clinicopathological features(sex,age,tumor size,tumor site differentiation,Lauren classification,tumor TNM staging,depth of invasion,lymph node metastasis).Kaplan-Meier method and Log-rank test were used to analyze the relationship between Her-2 protein expression and prognosis.Cox regression was then used for multivariate analysis to determine that it could serve as an independent predictor of prognosis in gastric cancer patients.Results: 1.The positive rate of Her-2 in 192 cases was 19.79%(38/192);2.The rates of HER-2 positive expression in male and female patients are 20.45% and 18.33% respectively,and positive expression rates in the age of diagnosis <60 years and ≥60 years 19.00%,21.13%;The positive expression rates in well differentiated group,moderately differentiated group and poorly differentiated group were 21.42%(6/28),28.57%(10/35)and 17.15%(22/129)respectively;The positive expression rates of Her-2 in gastric cancer specimens with long diameter <5 cm and long diameter> 5 cm were 22.13%(27/122)and 15.71%(11/79)respectively.In the degree of tumor infiltration T stage,the positive rates of T1,T2,T3 and T4 were 27.72%(6/22),18.91%(7/37),14.75%(9/61)and 22.22%(16/72)respectively;In the lymph node metastasis,N0,N1,N2,N3,respectively,the positive rate was 20.00%(4/70),15.62%(5/32),26.00%(13/50),15.00%(6/40);The positive rates of TNM stage Ⅰ,Ⅱ,Ⅲ and Ⅳ were 24.39%(10/41),18%(9/50),19.19%(19/99)and 0.00%(0/2)respectively,Clinicopathological features between the above each group was no significant difference(P> 0.05).3.In the classification of tumor site,the positive rate of Her-2 expression at the cardia was 40.00%,followed by 18.18% of gastric body and 15.18% of gastric antrum,respectively;In Lauren’s classification,the positive expression rate of Her-2 in intestinal-type gastric cancer was significantly higher than that in mixed-type gastric cancer(30.90% VS 6.38%),Among the above groups was statistically significant(P <0.05).4.Univariate the log-rank survival analysis prognostic method was shown that the presence of Her-2 positive gastric cancer,median survival time was significantly shorter than the Her-2 negative(32.73VS58.60),(P <0.05).5.Cox proportional and hazardous regression model analysis showed that HER-2 expression was an independent parameter of gastric cancer prognosis(P<0.05).Conclusion: 1.Her-2 is over-expressed in gastric cancer and is closely related to the location of gastric cancer and Lauren’s classification of gastric cancer.2.Her-2 protein overexpression group in gastric cancer patients had a worse prognosis than negative group.3.Her-2 overexpression can be used as an independent and prognostic factor in patients with gastric cancer. |
PDF Full Text Request